97200 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells Carcino-embryonic Antigens
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#302Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
#303ANTIBODIES TO CEACAM1 AND KINASE INHIBITORS FOR TREATING BRAF-MUTATED CELLS
#304DISEASE THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND T CELLS (CAR-T) OR NK CELLS (CAR-NK) EXPRESSING CAR CONSTRUCTS
#305Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy
#306Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules
#307Antibody-SN-38 immunoconjugates with a CL2A linker
#308Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
#309BISPECIFIC ANTIBODY WITH TWO SINGLE-DOMAIN ANTIGEN-BINDING FRAGMENTS
#310Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
#311Cancer markers and methods of use thereof
#312Disease therapy by inducing immune response to Trop-2 expressing cells
#313Immunoconjugates
#314Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
#315Antibody-SN-38 immunoconjugates with a CL2A linker
#316BISPECIFIC NANOBODIES
#317DELIVERY SYSTEM FOR CYTOTOXIC DRUGS BY BISPECIFIC ANTIBODY PRETARGETING
#318ANTI-CEA ANTIBODIES
#319Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules
#320Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#321T-cell redirecting bispecific antibodies for treatment of disease
#322T-Cell Redirecting Bispecific Antibodies for Treatment of Disease
#323Interferon lambda-antibody complexes
#324SINGLE CHAIN BINDING MOLECULES COMPRISING N-TERMINAL ABP
#325Anti-CEACAM5 antibodies and uses thereof
#326Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#327Production of antibody formats and immunological applications of said formats
#328Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof
#329SELECTION OF FAB FRAGMENTS USING RIBOSOMAL DISPLAY TECHNOLOGY
#330Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#331Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
#332Method for refolding antibody, process for producing refolded antibody, refolded antibody, and uses thereof
#333Antibody-drug conjugates and uses thereof
#334Class I anti-CEA antibodies and uses thereof
#335Antibody-SN-38 immunoconjugates with a CL2A linker
#336Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof
#337Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#338Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#339Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#340Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#341Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#342Modulation of immunity and CEACAM1 activity
#343CEACAM1 mediated protective immunity
#344Disease therapy by inducing immune response to Trop-2 expressing cells
#345Class I anti-CEA antibodies and uses thereof
#346Protein constructs designed for targeting and lysis of cells
#347Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
#348Stably tethered structures of defined compositions with multiple functions or binding specificities
#349N-domain of carcinoembryonic antigen and compositions, methods and uses thereof
#350Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
#351Methods and compositions for generating bioactive assemblies of increased complexity and uses
#352Anti-CEACAM1 recombinant antibodies for cancer therapy
#353Class I anti-CEA antibodies and uses thereof
#354Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
#355Bispecific T cell activating antigen binding molecules
#356Antibody-SN-38 immunoconjugates with a CL2A linker
#357Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#358Anti-CEA antibodies
#359Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#360Tetrameric cytokines with improved biological activity
#361Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
#362Combination therapy for inducing immune response to disease
#363Combination IL-2 immunoconjugate therapy
#364T-cell redirecting bispecific antibodies for treatment of disease
#365Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
#366Antigen binding formats for use in therapeutic treatments or diagnostic assays
#367Class I anti-CEA antibodies and uses thereof
#368Dock-and-Lock (DNL) Complexes for delivery of interference RNA
#369Pharmaceutical compositions with resistance to soluble CEA
#370Anti-CEACAM6 antibodies and uses thereof
#371Methods and compositions for generating bioactive assemblies of increased complexity and uses
#372FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1
#373Interferon lambada-antibody complexes
#374Antibody against carcinoembryonic antigen and uses thereof
#375Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock
#376Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
#377N-domain of carcinoembryonic antigen and compositions, methods and uses thereof
#378BINDING DOMAINS
#379Dye Conjugated Peptides for Fluorescent Imaging
#380Class I anti-CEA antibodies and uses thereof
#381Methods for Diagnosing The Malignant Potential of Pancreatic Cystic Lesions
#382Ultrafiltration concentration of allotype selected antibodies for small-volume administration
#383Covalent disulfide-linked diabodies and uses thereof
#384Multivalent Immunoglobulin-Based Bioactive Assemblies
#385Immunoconjugates
#386Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity
#387Anti-CEA antibodies
#388Design and Construction of Novel Multivalent Antibodies
#389Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO
#390Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
#391Mammalian cell lines for increasing longevity and protein yield from a cell culture
#392DR5—FAP bispecific death receptor agonistic antibodies
#393Therapeutic using a bispecific antibody
#394FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF
#395Pharmaceutical antibody compositions with resistance to soluble CEA
#396CAB molecules
#397Fully human antibodies specific to CADM1
#398Dock-and-Lock (DNL) Complexes for Disease Therapy
#399Mammalian cell lines for increasing longevity and protein yield from a cell culture
#400Therapeutic and diagnostic conjugates for use with multispecific antibodies
#401Antibody therapy
#402Tetrameric cytokines with improved biological activity
#403Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
#404Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
#405Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
#406Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
#407Chimeric activators: quantitatively designed protein therapeutics and uses thereof
#408FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF
#409Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#410Methods for Protein Expression in Mammalian Cells in Serum-Free Medium
#411Multivalent carriers of bi-specific antibodies
#412Methods and compositions for generating bioactive assemblies of increased complexity and uses
#413IMMUNOGLOBULIN CONSTRUCTS
#414Antibody therapy
#415Dock-and-lock (DNL) vaccines for cancer therapy
#416Cab Molecules
#417Stably tethered structures of defined compositions with multiple functions or binding specificities
#418Dock-and-lock (DNL) complexes for delivery of interference RNA
#419Multivalent immunoglobulin-based bioactive assemblies
#420Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof
#421IN SITU IMMUNIZATION
#422Class I anti-CEA antibodies and uses thereof
#423Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
#424AMINO ACID SEQUENCES DIRECTED AGAINST HETERODIMERIC CYTOKINES AND/OR THEIR RECEPTORS AND POLYPEPTIDES COMPRISING THE SAME
#425Framework residue substituted humanized COL-1 antibodies and their use
#426Rationally-designed anti-αβν6 integrin antibody MFEVP1 and variants thereof, method of making such antibody and the use thereof in treating and diagnosis of disease
#427METHOD FOR OBTAINING POLYPEPTIDE CONSTRUCTS COMPRISING TWO OR MORE SINGLE DOMAIN ANTIBODIES
#428Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
#429Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
#430Mammalian cell lines for increasing longevity and protein yield from a cell culture
#431Engineered proteins with high affinity for DOTA chelates
#432Protein increasing cell infectivity of herpes simplex virus and use thereof
#433Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
#434Antibody therapy
#435Tetrameric cytokines with improved biological activity
#436Strategies for improved cancer vaccines
#437Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies
#438Chimeric, human and humanized anti-CSAP monoclonal antibodies
#439Production and use of novel peptide-based agents for use with bi-specific antibodies
#440INTRANASAL DELIVERY OF POLYPEPTIDES AND PROTEINS
#441Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
#442TYROSINE PHOSPHORYLATION SITES
#443Dock-and-lock (DNL) vaccines for cancer therapy
#444Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
#445Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
#446Production and use of novel peptide-based agents with bispecific antibodies
#447Single-chain Multiple Antigen-binding Molecule, Its Preparation and Use
#448PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#449Vaccine and Antigen Mimotopes Against Cancerous Diseases Associated with the Carcinoembryonic Antigen CEA
#450Bispecific Antibody Point Mutations for Enhancing Rate of Clearance
#451Multivalent immunoglobulin-based bioactive assemblies
#452Mammalian cell lines for increasing longevity and protein yield from cell culture
#453Multivalent carriers of bi-specific antibodies
#454Production and use of novel peptide-based agents for use with bi-specific antibodies
#455PHARMACEUTICAL ANTIBODY COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA
#456Pharmaceutical compositions with resistance to soluble CEA
#457Production of antibody formats and immunological applications of said formats
#458Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
#459Methods and compositions for generating bioactive assemblies of increased complexity and uses
#460Stably tethered structures of defined compositions with multiple functions or binding specificities
#461Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
#462COMBINATION OF TUMOR-ASSOCIATED SURFACE PROTEIN ANTIGENS AND TUMOR-ASSOCIATED SUGARS IN THE TREATMENT AND DIAGNOSIS OF CANCER
#463Gene Engineering Recombinant Anti-CEA, Anti-CD3, And Anti-CD28 Single-Chain Tri-Specific Antibody
#464Methods for protein expression in mammalian cells in serum-free medium
#465Antibody therapy
#466Production of cancer-specific antibodies in plants
#467Production and use of novel peptide-based agents for use with bi-specific antibodies
#468Protein constructs designed for targeting and lysis of cells
#469Host Cells Containing Multiple Integrating Vectors
#470Vector for efficient selection and/or maturation of an antibody and uses thereof
#471Gold nanoparticles for selective IR heating
#472Framework residue substituted humanized COL-1 antibodies and their use
#473Chimeric, human and humanized anti-CSAp monoclonal antibodies
#474Chimeric, human and humanized anti-CSAP monoclonal antibodies
#475Chimeric, human and humanized anti-CSAp monoclonal antibodies
#476Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
#477Nucleic acids encoding polyvalent protein complexes
#478Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
#479CEACAM1 mediated protective immunity
#480CAB molecules
#481Chimeric, human and humanized anti-CSAP monoclonal antibodies
#482Humanized anti-CEA T84.66 antibody and uses thereof
#483Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
#484PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#485Antibodies against tumor surface antigens
#486Multicomponent conjugates which bind to target molecules and stimulate T cell lysis
#487PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#488Therapeutic using a bispecific antibody
#489ANTIBODY THERAPY
#490Antibody fragments specific for human carcinoembryonic antigen (CEA)
#491Methods and materials relating to novel polypeptides and polynucleotides
#492Multivalent immunoglobulin-based bioactive assemblies
#493Protein nmb0928 and use thereof in pharmaceutical formulations
#494Modulation of immunity and CEACAM1 activity
#495Methods and compositions for generating bioactive assemblies of increased complexity and uses
#496CEACAM1 based cancer therapy and diagnosis
#497Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
#498Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
#499Mammalian cell lines for increasing longevity and protein yield from a cell culture
#500Anticarcinoma antibodies and uses thereof
#501Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
#502Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof
#503Stably tethered structures of defined compositions with multiple functions or binding specificities
#504Methods and compositions for milieu-dependent binding of a targeted agent to a target
#505Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s)
#506Methods and compositions for increasing longevity and protein yield from a cell culture
#507Production and use of novel peptide-based agents for use with bi-specific antibodies
#508Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
#509Composition for delivering an agent to a target cell and uses thereof
#510CEA binding agents and compositions to reverse CEA-mediated tumorigenic effects on human cancer cells, restore sensitivity to drug induced apoptosis and uses thereof
#511Production and use of novel peptide-based agents with bispecific antibodies
#512Transgenically produced fusion proteins
#513Methods and devices for targeting a site in a mammal and for removing species from a mammal
#514Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer
#515Humanized anti-CEA T84.66 antibody and uses thereof
#516Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
#517Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
#518Chimeric, human and humanized anti-CSAp monoclonal antibodies
#519Specific antibody fragments for the human carcinoembryonic antigen (cea)
#520CEA/NCA-based differentiation cancer therapy
#521Antibodies against tumor surface antigens
#522Production of cancer-specific antibodies in plants
#523Fluorinated carbohydrate conjugates
#524Host cells containing multiple integrating vectors
#525Multivalent carriers of bi-specific antibodies
#526CDR grafted type III anti-CEA humanized mouse monoclonal antibodies
#527Compositions and methods for producing vascular occlusion
#528Expression vectors
#529Complex formation for the stabilisation and purification of proteins of interest
#530Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
#531Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
#532APC targeting conjugate, an antigen-presenting cell contacted with such conjugate, their medical use, and methods of production
#533Composition for delivering an agent to a target cell and uses thereof
#534Single-chain multiple antigen-binding molecule, its preparation and use
#535Polyvalent protein complex
#536Therapeutic and diagnostic conjugates for use with multispecific antibodies